According to JMP Securities, Oncothyreon ONTY price target is raised to $14.
JMP said that near-term catalysts could unlock potential upside; reiterate Market Outperform rating and raising price target to $14 from $8 for Oncothyreon. "We are increasing our sum-of-the-parts driven price target to $14, to reflect higher peak sales projections for Stimuvax and inclusion of pipeline value, now comprising $9 for Stimuvax (previously $8) and $4.50 for PX-866, ONT-10 and cash."
Oncothyreon closed yesterday at $6.22.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in